← Back to Search

ADRB3 Agonist

Mirabegron for Obesity

Phase 1
Recruiting
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Males and females 18-70 years old
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 28 days (± 14 days)
Awards & highlights

Study Summary

This trial will study how a drug, mirabegron, affects gene expression in fat tissue of people who are lean and obese. 3 visits to the study center will be required.

Who is the study for?
This trial is for adults aged 18-70 with prediabetes and obesity (BMI 30-40) or lean individuals (BMI <27) with normal glucose levels. Participants must not be on certain heart medications, have a history of eating disorders, substance abuse, bladder issues, diabetes, heart disease or other conditions that affect study participation.Check my eligibility
What is being tested?
The study tests how the gene expression in fat tissue changes after a single dose of mirabegron in lean and obese participants. It's an exploratory phase 1 trial involving three visits: screening, pre-dose biopsy, and post-dose biopsy to assess the effects on ADRB3 signaling pathways.See study design
What are the potential side effects?
Potential side effects from mirabegron may include increased blood pressure, urinary tract infections (UTIs), headache, dizziness, nausea or allergic reactions. Since it affects bladder muscles too much can lead to inability to empty the bladder.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 70 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~28 days (± 14 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 28 days (± 14 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ADRB3 gene expression
ADRB3 protein levels
Free Fatty Acid measured Catecholamine Sensitivity
+1 more
Secondary outcome measures
FGF-21 Adipokine Gene Expression
IL-6 Adipokine Gene Expression
Other outcome measures
ADRB3 Signaling Pathway

Side effects data

From 2019 Phase 4 trial • 28 Patients • NCT02086188
7%
urinary tract infection
7%
gastritis
7%
fatigue
7%
asthma
7%
diarrhea
7%
headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Mirabegron

Trial Design

2Treatment groups
Experimental Treatment
Group I: Obese GroupExperimental Treatment1 Intervention
Single dose, 100mg oral mirabegron in Obese Insulin Resistant adults
Group II: Non-Obese GroupExperimental Treatment1 Intervention
Single dose, 100mg oral mirabegron in Non-Obese adults
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mirabegron
2008
Completed Phase 4
~18640

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of California, San DiegoLead Sponsor
1,122 Previous Clinical Trials
1,521,004 Total Patients Enrolled
53 Trials studying Obesity
7,482 Patients Enrolled for Obesity

Media Library

Mirabegron (ADRB3 Agonist) Clinical Trial Eligibility Overview. Trial Name: NCT05634174 — Phase 1
Obesity Research Study Groups: Obese Group, Non-Obese Group
Obesity Clinical Trial 2023: Mirabegron Highlights & Side Effects. Trial Name: NCT05634174 — Phase 1
Mirabegron (ADRB3 Agonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05634174 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is recruitment ongoing for this investigation?

"As per clinicaltrials.gov, the advertised study is not currently seeking participants; it was initially posted on February 1st 2023 and last updated November 21 2022. However, there are 182 other trials that are still actively enrolling patients."

Answered by AI

Are individuals of 45 years or more able to partake in this research?

"This particular medical trial has established that only those between 18 and 70 years old are suitable candidates; however, there is an abundance of other trials available for minors and elderly individuals. Specifically, 9 studies exist for persons under the age of 18 while 146 have been created to cater to seniors above 65."

Answered by AI

Am I eligible to join the experiment?

"Requisites for admission to this trial include obesity, prediabetes and an age bracket between 18-70 years old. The study is looking to recruit a total of 40 individuals."

Answered by AI

What is the overall risk for individuals partaking in Non-Obese Group activities?

"Minimal data exists supporting Non-Obese Group's safety and efficacy, thus they scored a 1 on our team at Power's scale."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
ADRB3 Signaling Pathway in Human Adipose Tissue
Vala Hamidi 2023. "ADRB3 Signaling Pathway in Human Adipose Tissue". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05634174.
~27 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top